Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
/
RSS Feed
Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
You may also like...
Stage I to III breast cancer: radiation therapy to chest lymph nodes extends life 26 Oct, 2013 - Breast Lumps Between Mammography Visits Signal High Risk 19 Apr, 2018
Bevacizumab: New Standard for Non-Small Cell Lung Cancer? 16 Mar, 2008 - Gastrointestinal Cancers: Progress with Targeted Therapies 27 Jan, 2008
